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Patient]. A 35-year-old woman with a history of type-I diabetes
mellitus since age 8 and diabetic nephropathy was evaluated for
participation in a study of the relationship between levels of
advanced glycation and renal-vascular complications of diabetes.
Five years ago, uncontrolled diabetes (hemoglobin Al 11%) had
been accompanied by mild hypertension, background retinopathy,
proteinuria (1.5 g/24 hr), creatinine clearance 90 ml/min/1.73 m2,
and an elevated serum cholesterol.
At the time of current evaluation, the patient had a blood
pressure of 160/114 mm Hg and a regular heart rate of 72
beats/mm. The rest of the physical examination was normal, as
was her electrocardiogram. Laboratory evaluation revealed nor-
mal electrolytes with borderline hyperkalemia (5.1 mEq/liter);
serum creatinine, 2.0 mg/dI; creatinine clearance, 70 mI/mm;
urinary albumin excretion (UAE) rate, 24 i1g/min (normal <15
tg/min or 22 ng/24 hr). Hemoglobin Al was 12.5%; serum LDL
cholesterol, 208 mg/dl; HDL cholesterol, 48 mg/dl.
As part of the study, the level of hemoglobin-AGE was
determined and was 9.7 U/mg hemoglobin (normal range: 3—5
U/mg). The patient agreed to participate in a 28-day double-blind,
placebo-controlled trial of an advanced glycation end product
(AGE) inhibitor, aminoguanidine. After 28 days of treatment with
aminoguanidine (400 mg orally twice daily), during which no
adverse effects were noted, Hb Al was still 12%. Hb-AGE,
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however, had fallen to 5 U/mg and serum LDL cholesterol to 168
mg/dl (HDL cholesterol 52 mg/dl).
Patient 2. A 52-year-old non-diabetic woman with a history of
chronic renal failure secondary to chronic pyelonephritis and
hypertension had been treated with hemodialysis for one year.
She was admitted to a study of the long-term effects of intensive
hemodialysis on circulating levels of AGE-modified proteins and
lipoproteins, known to be elevated in non-diabetic patients with
end-stage renal disease (ESRD). At that time, the patient had a
blood pressure of 165/100 mm Hg; pulse, 68 and regular; serum
creatinine, 3.2 mg/dl; Hb Al, 4.1%; Hb-AGE, 5.5 U/mg; and
serum AGE, 88 U/ml (normal range 3—20 U/mI). Her serum LDL
apolipoprotein B was elevated at 96 mg/dl, as was AGE-ApoB at
288 U/mg ApoB. Following a two-month period of therapy on a
high-flux hemodialyzer (AN69), her Hb Al and Hb-AGE were
still within normal limits (3.6% and 4.0 U/mg, respectively). Total
serum AGE was 60 U/mI and AGE-ApoB, 210 U/mg ApoB.
Interestingly, serum LDL ApoB had fallen to within the normal
range (50 mg/dl).
Discussion
DR. HELEN VLASSARA (Professor and Head, Laboratory of Dia-
betes and Aging, Picower Institute for Medical Research, Manhasset
New York): These two cases represent typical examples of ad-
vanced renal failure due to widely different causes, long-standing
diabetes and chronic pyelonephritis. We know that diabetic
nephropathy afflicts 35% to 45% of patients with insulin-depen-
dent diabetes mellitus (IDDM) and non-insulin-dependent diabe-
tes mellitus (NIDDM) with similar pathologic characteristics [1,
2]. We also know that all nephropathies, independent of causality,
ultimately converge onto a common downward course of glomer-
ular sclerosis associated with renal failure [1—3]. Diabetic ne-
phropathy now is the single most common cause of ESRD in the
United States, accounting for more than 30% of all ESRD
patients [4]. According to the United States Renal Data System
(USRDS), the survival of diabetic patients treated with some form
of dialysis is greatly reduced compared with that of non-diabetic
patients. Two-year survival rates are 5 1.4% for non-diabetics and
43.9% for diabetics, respectively. On the other hand, for diabetics
with renal transplants, the 2-year survival rate is 88.1%, which in
fact, is almost identical to the overall survival of 88.4%. This
similarity points to a significant advantage of renal transplantation
therapy for diabetic and nondiabetic patients alike. Persistent
hyperglycemia is a prerequisite for tissue and end-organ damage
in diabetes mellitus [5]. Much recent evidence has linked chronic
hyperglycemia to the accumulation of the late products of glu-
cose-protein interaction, called "advanced glycation end prod-
ucts" (AGEs), and to a variety of late complications, including
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diabetic nephropathy [6, 7]. A similar, but slower accumulation of
AGEs occurs normally with aging [6, 7]. We have reported that
circulating and arterial tissue AGE levels increase dramatically in
diabetic as well as in non-diabetic patients with ESRD [8, 9]; this
finding has been confirmed by other laboratories [10, 11] and has
been extended to include elevated levels of specific AGE-modi-
fied serum proteins, such as AGE-lipoproteins [12] and
microglobulin [13, 14] both in diabetic and non-diabetic uremic
patients. Today, I will focus on some novel insights into mecha-
nisms of tissue damage in renal disease of diabetic or non-diabetic
etiology, which may provide a rationale for new and better
therapeutic interventions.
The elusive nature of AGEs
The emergence of AGEs resulting from the spontaneous
reaction between glucose and proteins—herein referred to as
"first generation" AGE—occurs most noticeably on long-lived
structural proteins [15, 161. A significant correlation has been
shown between the levels of these irreversible modifications and
the presence and severity of diabetic complications [7, 11].
The structural elucidation of specific AGEs remains a problem,
stemming largely from their heterogeneity and tendency to be
unstable during isolation. A few such adducts have been structur-
ally identified thus far through the use of a variety of direct or
indirect criteria, including 2(2-furoyl)-4(5)-(2-furanyl)- 1 H-imida-
zole (FF1), alkyl-formyl-diglycosylpyrrole (AFGP), pyrraline, car-
boxy-methyl-lysine (CML), and pentosidine [6, 7, 171. Two
epimers of a new lysine-lysine cross-linking structure incorporat-
ing two moles of carbohydrate, named "crosslines A and B," were
isolated from in-vitro incubations, but not as yet from in-vivo
sources [18].
Sensitive and specific immunochemical methods in the mean-
time have supported the in-vivo existence of structurally related
compounds, although the precise structural features of dominant
"native" AGEs remain elusive. An important feature of the
anti-AGE antibodies generated against AGEs prepared in vitro
under physiologic conditions [19—21] has been the identification
of an apparently major class of cross-reactive AGE epitope(s) that
are common to proteins modified by AGE in vivo, and which
includes AGEs that are inhibited by aminoguanidine, a pharma-
cologic inhibitor of advanced glycation [22].
A close correlation exists between AGE formation and the
physicochemical changes taking place on connective tissue in
diabetes or in aging, including collagen-to-collagen cross-linking
and tissue rigidity [6, 7]. Furthermore, AGE-mediated cross-link
formation decreases the solubility and susceptibility of proteins to
enzymatic digestion. These properties are particularly relevant to
the function of connective tissue and extracellular matrix collagen,
as they are associated with increases in thickness, rigidity, and
breaking time, changes typically observed in diabetic and in aging
tissues. In addition, AGE moieties formed on matrix components,
such as on vessel wall and kidney, retain their ability to cross-link
and trap a variety of plasma proteins, most notably lipoprotein
and immunoglobulins [6, 7].
Advanced glyclation end products formed in vascular matrix
might interfere chemically with the action of nitric oxide (No.),
the active constituent of endothelium-derived relaxing factor
(EDRF) [23]. This possibility implicates AGEs in the defective
vascular relaxation and hypertension associated with both diabe-
tes and aging [24—26].
In-vitro studies have demonstrated that collagen-bound AGE
moieties react directly with nitric oxide to inactivate it [23], while
in experimentally induced diabetes, defective vasodilatory re-
sponses develop in a pattern consistent with the quenching of
nitric oxide by AGEs at the subendothelial level. Further confir-
matory evidence for the role of AGEs as modulators of vascular
tone in diabetes came from our study of the effect of exogenous
administration of AGE-modified proteins to non-diabetic animals
[271. Significant impairment of vasodilation occurred in AGE-
treated normoglycemic rats and rabbits; this effect was diminished
by the AGE inhibitor aminoguanidine.
Endothelium-derived nitric oxide also exerts potent borneo-
static and antiproliferative effects on different cell types and has
been proposed to be essential for the mitogenic quiescence of
subendothelial vascular smooth muscle cells. AGE-modified ma-
trix proteins specifically block the antiproliferative effect of nitric
oxide on cultured vascular smooth muscle cells and renal mesan-
gial cells in vitro [281. These data implicate tissue AGEs as
important modulators of nitric oxide-mediated responses; how-
ever, further studies are required to confirm the role of NO • in
the evolution of the proliferative vascular and glornerular lesions
present in diabetes mellitus.
Dyslipidemias characterized by various patterns of increased
levels of LDL, VLDL, and IDL are not only common in diabetics
and uremics with or without diabetes, but also increase the
likelihood that these patients will suffer from the atherosclerotic
complications of heart attack and stroke. Low-density lipoprotein
is the major lipoprotein component responsible for transferring
both exogenously absorbed and endogenously synthesized lipids
to peripheral tissues. Biochemical modifications that affect the
structural and functional integrity of LDL are believed to be
central to atherogenesis. In addition to the oxidative modification
that affects the clearance of LDL, a new class of chemical
modifications, which can render it more atherogenic, results from
advanced glycation [29].
Clinical studies indicate an increased level of AGEs on LDL
obtained from diabetic compared to normal individuals [12, 29].
Of note, AGE moieties were present on both the apoprotein and
lipid components of LDL. ApoB-AGE levels were increased more
than twofold in the diabetic samples, and lipid-AGE levels were
elevated almost fourfold in diabetic patients [12, 29]. It is inter-
esting that LDL isolated from diabetic individuals displayed an
increased oxidative modification as well [29]. It is unclear whether
these values reflect an increase in lipid oxidation in vivo, or simply
an increase in the susceptibility of LDL to oxidation after it is
removed from plasma. Nevertheless, these data indicate that LDL
oxidation occurs concomitantly with advanced glycation and that
AGE formation might be a primary mechanism responsible for
the pathogenetic modification of the LDL particle.
Indeed, the presence of amino groups on phospholipids such as
phosphatidylethanolamine and phosphatidylserine suggests that
glucose could react directly with lipid amines to form AGEs. The
intermolecular oxidation-reduction reactions, known to occur
during advanced glycation, might then oxidize fatty acid residues
independently of the transition metals or exogenous, free-radical-
generating systems that have frequently been added in experimen-
tal studies. When free-amine-containing phosphatidylethanol-
amine was incubated with glucose and metal chelators, AGEs as
well as oxidation products formed as a function of glucose
concentration [29]. Both processes were effectively prevented in
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Mouse, rat, human/p60/OST, p90/87K-H,
galectin-3
Rat, human, bovine/p60/OST,
p90/87K-H, galectin-3, RAGE
Mouse, rat, human/p60/OST, p90/87K-H,
galectin-3
Rat, human/p60/OST, p90/87K-H,
galectin-3, RAGE
Rat, human/p60/OST, p90/87K-H,
galectin-3, RAGE
Function
AGE-ligand binding, endocytosis, degradation
Cytokine production (TNFI3, IL-Icr)
Growth factor induction (PDGF, IGF-IA)
Chemotaxis
Upregulation by TNFI3
Downregulation by insulin
Ligand binding, receptor regulation by PHA,
LPS, TNF/3
Tnterferon-y production
Ligand binding, transcytosis, degradation
Permeability
Tissue factor, thrombomodulin
VCAM-I, ICAM-1
Binding, endocytosis, degradation
' Fibronectin, collagen IV, laminin
Growth factor induction (PDGF, TGFl)
Ligand binding
EGF and EGF-receptor mRNA
' Proliferation
Ligand binding
I Proliferation
the presence of the AGE inhibitor aminoguanidine. Of note,
lipids lacking free amines, such as phosphatidylcholine, were not
able to react with glucose, nor could they form oxidation products;
this fact points to amine-glucose interactions as a primary medi-
ator of fatty acid oxidation in vivo.
AGEs interact with cellular receptors to elicit multiple effects
In the last decade, our understanding of the biology of AGEs
has expanded significantly. Given the abundance of AGEs in both
the extra- and intravascular compartments, studies probing the
complex cellular interactions with AGEs have yielded new insights
regarding the pathogenetic aspects of this ubiquitous process.
Initially, it was observed that both in-vivo formed and in-vitro
synthesized AGEs are recognized by distinct macrophage AGE
receptors [30, 31]. Two AGE-binding proteins (60 kD and 90 kD)
isolated from rat liver membranes were identified on rat mono-
cyte/macrophage surfaces [32]. These proteins were recently
found to be homologous to OST-48 [33] and 80 K-H [341,
respectively [351. Specific antisera raised against these two AGE-
receptor proteins subsequently confirmed a related pattern of
receptor expression and properties on cells other than rat macro-
phages (for example, vascular endothelium, mesangium) as well as
in species other than rat (for example, mouse and human),
probably pointing to a highly conserved family of proteins (Table
1). Based on the range of cellular responses thus far associated
with AGE-receptor/ligand interactions, for example, monocytic
migration, activation, and cytokine and growth factor secretion, a
regulatory system has begun to emerge via which macrophages,
while selectively removing AGE-modified macromolecules, also
can participate in repair/remodeling processes [36, 37].
Other members of the hemopoietic lineage subsequently were
found to express these molecules on their surface. Of particular
interest, resting human and rat CD4+ and CD8+ T-cells were
found to constitutively express such sites and to bind AGE
proteins, whereas phytohemagglutinin (PHA) prestimulation of
T-cells resulted in AGE receptor upregulation and in IFNy
synthesis and release [38]. These results suggest that AGE-
activated IFNy-producing T-cells may contribute to tissue damage
in cooperation with primed macrophages. This concept is consis-
tent with evidence that activated lymphocytes found in atheroscle-
rotic lesions might be active participants in an immune-like
response underlying atherogenesis [39]. Within vascular tissues,
AGE accumulation might serve as a primary stimulus for tissue
macrophage and T-cell activation in such lesions.
Additional cell-surface-binding proteins for AGE determinants
have been identified and cloned from other tissues and cells of
interest, for example, endothelium [40—42]. These proteins in-
clude a novel 35 kD member of the immunoglobulin superfamily
of receptors, named RAGE, and an 80 kD protein, with complete
sequence homology to lactoferrin (LF). Using immunohistochem-
ical and in-situ hybridization techniques, Brett et al found RAGE
expression to be localized to monocytes and a variety of tissues,
including neural tissues and skeletal and smooth muscle [43].
Another molecule has recently been added to the AGE-
recognizing proteins. A 32 kD protein, now referred to as
galectin-3, but previously known as Mae-2 or carbohydrate bind-
ing protein-35 (CBP-35), is expressed on macrophages and other
cells and exhibits high-affinity binding for AGE ligands (Kd, 3.5 X
io M') compared with that of other carbohydrates (1 X i0
M1) [44]. Binding of AGE to galectin-3 occurs within the 18 kD
C-terminal peptide and promotes high-molecular-weight complex
formation with the AGE ligand and with other membrane-
associated receptor molecules on the cell surface. The significance
of this finding is under investigation.
The protein sequence, ligand specificity, and functional differ-
ences between these molecules and the macrophage AGE-binding
polypeptides I have described have led us to speculate that there
may exist a number of AGE-binding proteins with or without
"receptor" characteristics that might contribute to diverse cellular
functions, for example, chemotaxis, adhesion, activation, cell
growth and differentiation, but also to clotting or vascular harrier
Cell type
Table 1. AGE receptor expression and function
Species/AGE receptor components
Mouse, rat, human/p60/OST, p90/80K-H,
galectin-3, RAGE
Monocyte/macrophage
T-!ymphocyte CD4+, CD8+ T-cells
Endothelial cell
Mesangial cells
Fibroblast
Smooth skeletal muscle cells,
neural cells, glia
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integrity. In this context, in-vitro evidence indicates that AGE-
endothelial cell interactions result in increased endothelial cell-
associated procoagulant activity and vascular permeability [40].
Of particular relevance has been the identification of murine and
human mesangial cell AGE-binding sites [45, 46j. An important
function of this group of mesangial cell AGE-receptors probably
is the regulation of extracellular matrix (ECM) synthesis and
secretion. Exposure of cultured mouse mesangial cells to AGE-
BSA results in a receptor-mediated upregulation of mRNA and
protein secretion of matrix proteins, for example, al type-IV
collagen and laminin A, Bi, and B2. Of note, the collagen alIV
mRNA increase initiated by the AGE receptors appeared to be
mediated, at least in cultured cells, by PDGF [46].
AGEs and the kidney: Animal and human studies
Despite the mounting in-vitro evidence, only recently did direct
in-vivo evidence elucidate the pathogenetic influence of AGE
receptor-ligand interactions. Studies in normal rats and rabbits
demonstrated that the short-term administration of homologous
AGE albumin prepared in vitro can reproduce vascular defects
similar to those observed in culture as well as to those associated
with experimental diabetes, including vascular leakage, or unre-
sponsiveness to vasodilatory agents [27].
We subsequently attempted to determine the direct contribu-
tion of cellular AGE-dependent responses to the intact glomeru-
lar structure in vivo by examining selected molecular events
involved in mesangial cell responsiveness, such as the induction of
ECM or growth factor genes [47]. The study focused on micro-
dissected glomeruli following the injection of AGE-mouse serum
albumin (MSA) for 4 weeks and using competitive polymerase
chain reaction (PCR) assays to quantitate specific ECM gene
alterations. We observed a predominant increase in al type-IV
collagen and laminin BI mRNA only in the mice receiving
AGE-modified MSA [47]. Of note, the mRNA of another growth-
promoting molecule, TGF-pl, was significantly increased in the
AGE-treated mice [47]. Prolonged administration of AGEs to
nondiabetic rats resulted in glomerular hypertrophy, basement
membrane thickening, and mesangial ECM expansion consistent
with frank glomerulosclerosis (Fig. 1), which was associated with
significant proteinuria and albuminuria [48]. Similar administra-
tion of AGE to euglycemic rabbits induced substantial structural
changes in the aortic wall, such that atheroma formation was
vastly accelerated after a 10-day exposure to exogenous hyperlip-
idemia [49]. In all these studies, treatment with aminoguanidine
largely ameliorated the AGE-mediated pathology [27, 47, 48, 49].
All the foregoing evidence led us to speculate that the AGE-
receptor system represents a principal degradation mechanism for
AGE-modified tissue and cell components, capable of generating
small soluble AGE peptides and amino acids which, combined
with normal proteolysis of matrix components, gives rise to a class
of circulating, low-molecular-weight AGE-modified substances.
Levels of these substances likely depend on the underlying tissue
AGE levels and the activity of AGE receptor- and non-receptor-
dependent removal systems. The degradation products of AGE-
modified proteins presumably are carried into the circulation to
be cleared by the kidneys in a clearance-dependent manner, since
in serum, the levels of AGE peptides correlate with renal function
[8, 9, 11]. In normal individuals, renal clearance of AGE peptides
is estimated to be 0.72 ml/min [91. Diabetic individuals with
normal renal clearance also can clear AGE peptides at the same
rate; however, progressive loss of renal function is associated with
increasing circulating AGE levels, up to eightfold in diabetic
patients with ESRD [8, 9].
Diabetic patients with renal disease are far more susceptible to
cardiovascular complications, mostly because of accelerated ath-
erosclerosis [4]. The pronounced increase in AGE degradation
products in the circulation of diabetic anephric patients has raised
the possibility that uncleared recirculating AGEs include a class of
potentially reactive, and therefore "toxic," intermediates. This
"toxic" potential was in fact suggested by in-vitro studies showing
that small-size AGE peptides, when isolated from human serum
or proteolytically produced from in-vitro formed AGE albumin,
become covalently incorporated into target proteins, such as
normal collagen or low-density lipoprotein (LDL), producing
AGE collagen [9] and AGE LDL [12].
The in-vitro studies presented have generated a search for
in-vivo evidence of the "reactivity" of AGE peptides. These
attempts, for instance, have measured levels of AGEs incorpo-
rated on plasma proteins, such as ApoB LDL, a highly athero-
genic macromolecule, or /32-microglobulin from patients with
renal failure with or without diabetes (Fig. 2). Marked elevations
in AGE Apo B were found in plasma samples from diabetic as
well as non-diabetic patients with renal failure, compared to
normals, and diabetics with normal renal function [12]. Such AGE
modification of LDL delays clearance by the classic human LDL
receptor [12]. Miyata and colleagues provided further support for
the in-vivo "reactivity" of AGE peptides when they reported
abnormally high AGE-modified f32-microglobulin in serum and
urine of nondiabetic patients with hemodialysis-associated amy-
loidosis [13, 14].
The human and animal studies together point to an important
"side effect" of the in-vivo fate of AGE-modified proteins and
lipids, which might be due either to AGE receptor- or non-
receptor-dependent mechanisms: the catabolic products of AGE
macromolecules include reactive substances which, if not elimi-
nated by the kidney in a timely manner, can irreversibly alter
susceptible renal and extrarenal structures, producing "second" or
"third" generation AGEs. Thus, uncleared, reactive AGEs might
prove important potentiating factors of tissue damage (Table 2).
Novel therapeutic approaches
In 1986, the small nucleophilic compound aminoguanidine was
shown to be a potent and specific inhibitor of glucose-mediated
cross-linking and tissue damage in vivo [22]. The terminal amino
group of aminoguanidine, by virtue of its low pKa, reacts specif-
ically with glucose-derived reactive intermediates and prevents
protein-protein or protein-lipid cross-links from forming. Exper-
imental studies affirmed this mechanism of action of aminogua-
nidine. A number of studies subsequently have demonstrated an
efficacious role for aminoguanidine in preventing either AGE
formation or diabetes-related complications in vivo in experimen-
tal animals [50—65]. Diabetic rats treated with aminoguanidine,
for example, exhibit significantly less collagen-linked fluorescence
and cross-linking in the vascular wall than do untreated diabetic
controls [52, 58, 63]. Other studies have demonstrated a decrease
in AGE accumulation and protein trapping in the glomerular
basement membrane of the kidney [51J. Aminoguanidine delays
the onset of diabetes-related retinal vascular lesions and improves
diabetic neuropathy as measured by several parameters [55—57,
60—621. Together, these results suggest that aminoguanidine
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Fig. 1. In-vivo AGE rat serum albumin (AGE-RSA)-mediated glomemlar disease is inhibited by aminoguanidine. A, B: Light microscopy (>< 200) C, D,
E: Electron microscopy (X 2500). Kidney sections from normal rats were treated either with AGE-modified rat serum albumin (AGE-RSA) (A, D),
native rat albumin (RSA) (C), or AGE-RSA + aminoguanidine (B, E). Significant ECM expansion, basement membrane thickening, and glomerular
sclerosis induced by AGE (A, D) was largely ameliorated in the presence of aminoguanidine (B, E) [481.
markedly inhibits advanced glycosylation and the AGE-mediated A limited but encouraging amount of information has been
tissue damage that occurs during chronic hyperglycemia. Ami- obtained from a small 28-day, double-blind, placebo-controlled
noguanidine has displayed little toxicity so far in clinical studies, human trial of aminoguanidine [65]. Measurements of the "late"
and trials aimed at evaluating its efficacy for a variety of diabetic glycation products formed on hemoglobin (Hb-AGE), relative to
complications are underway in the United States and Europe. the "early" product or Amadori compound, referred to as HbAIC,
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Fig. 2. Serum AGE-ApoB (A) and AGE-lipid (B) levels in normal patients (NL), diabetic patients with normal renal function (DM), nondiabetic patients
with end-stage renal disease (ESRD), and diabetics with renal failure (DM-ESRD). P < 0.001 (Student's t test) for each patient group with ESRD versus
control group with and without diabetes L121.
Table 2. Possible role of AGEs and AGE receptors
in diabetic complications
Diabetic atherosclerosis
Monocytic/macrophage chemotaxis activation
Q,itokine and growth factor release: IL-la, TNFf3, IGF-IA, PDGF, TGF/31
I Vascular matrix, vessel wall thickening, and vascular occlusion
Endothelial cell permeability and tissue factor activity
T-cell stimulation interferon-y production
I Macrophage uptake of AGE-LDL atheroma function
Diabetic renal disease
I Mesangial matrix synthesis
j' Basement membrane deposition
I Vascular permeability
I Growth factor secretion
Glomerular hypertrophy glomerulosclerosis
were performed on blood specimens obtained from a group of
diabetic patients undergoing treatment with the AGE inhibitor
aminoguanidine. The mean Hb-AGE value decreased signifi-
cantly as a result of aminoguanidine therapy. Aminoguanidine
treatment did not affect HbAIC values; thus, aminoguanidine is
specific for inhibition of advanced glycation reactions.
Aminoguanidine therapy also was associated with a 28% de-
crease in LDL cholesterol, a 19% decrease in total cholesterol,
and a 19% decrease in triglycerides in diabetic patients with
various degrees of renal insufficiency [12J. The demonstration of
decreased Hb-AGE levels [651 together with a lowering of plasma
LDL cholesterol [121 as a result of aminoguanidine therapy
provide the first direct pieces of evidence of this drug's potential
for preventing advanced glycation in humans. Aminoguanidine
and related advanced glycation inhibitors represent a new class of
drugs that eventually may find widespread use in patients with
diabetes, renal failure, or those who are particularly susceptible to
age-related vascular sequelae. At present, the development of
these compounds is in its infancy, and the full medical benefits
that might accrue from the use of aminoguanidine-like com-
pounds have yet to be evaluated.
Questions and answers
DR. NlcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): The level of
ambient glucose is an obvious determinant of the formation of the
AGE peptide and protein cross-links. Can you tell us a bit about
what additional factors determine their formation and whether
there is special susceptibility of certain amino groups and proteins
to cross-linking? What determines the migration of small AGE
compounds into the circulation? Does rigorous control of glyce-
mia in diabetes alter the level of AGE moieties?
DR. VLASSARA: Let me address the first question, which dealt
with the factors that determine susceptibility of proteins or lipids
to modification by AGEs. The rate and the degree of modification
that occur on any given protein has to do with a number of
parameters; the number of available amino groups, the position of
these amino groups, the microenvironment in which they exist, the
charge, pH, and the buffering capacity of the microenvironment
all greatly influence the rate by which the glucose-protein reac-
tions occur. Also, the life span of the protein is very important: the
longer the half-life of a protein, the greater its chances for
reacting with ambient glucose (for example, collagen, lens crys-
tallins, and myelin proteins).
Your second question had to do with the small-sized AGE
substances found in the circulation. These are small molecules,
between 2000 and 6000 daltons, and are believed to reflect the
constant influx from the tissues and from cellular debris, which is
ultimately cleared by the kidneys. Advanced glycation end prod-
ucts are found in the urine in substantial quantities as long as
renal clearance is more or less intact. We do not know very clearly
all the factors that may determine the movement of small AGEs
from the tissues into the bloodstream. One might consider first
the same factors that dictate the passage of any catabolic products
A
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of proteins or lipids from the tissue and extracellular compart-
ments through the lymph and the blood to their final elimination.
Other factors include the rate of AGE formation, the efficiency of
natural AGE removal mechanisms, for example, receptor-medi-
ated and extracellular proteolysis. Also, the rate at which AGEs
are excreted in the urine ultimately might be determined by how
reactive they are and by whether they will interact with other
proteins and cell surfaces as they pass through. Of note is the
recent observation that as kidneys age, the AGE clearance
decreases markedly [66]; this finding implies that the aging kidney
is less able to filter them.
DR. MADIAS: Can you show in the aging animal or in the aging
human that the level of these AGEs increases in serum?
DR. VLASSARA: Yes, we recently obtained evidence that circu-
lating AGEs increase in non-diabetic, senescent rats, although it is
difficult to demonstrate dramatic increases in serum until the
renal function declines significantly. To my knowledge, such
studies have not been done in humans.
DR. MADIAs: So aging itself without accompanying, indepen-
dent renal disease is associated with increased levels of AGE
compounds?
DR. VLASSARA: Tissue AGEs accumulate with age before
registering declining renal function. High serum AGEs, however,
are still technically difficult to detect in the absence of renal
disease. In the rats used in our study, renal function declined with
age [66]; this decline might explain our findings. We have not yet
completed similar studies carried out in elderly patients.
DR. MAIIAs: The other question I asked was whether tight
control of glycemia affects the level of AGE substances.
DR. VLASSARA: To my knowledge, such a clinical study has not
been performed. A few studies have been initiated along those
lines showing, for instance, that AGE-modified hemoglobin levels
can be normalized in diabetic patients after strict metabolic
control [671.
DR. MADIAs: Can you tell us a bit more about the expression of
receptors of AGE moieties on the mesangial cell and whether
there is any alteration in their functional expression in models of
renal disease?
DR. VLASSARA: The mesangial cell expresses all three compo-
nents of the AGE receptor described thus far, p90, p60, and
galectin-3, a well characterized surface activation marker. In
response to exposure to high levels of extracellular AGEs, these
cells produce growth factors and, as we have shown, a number of
key extracellular matrix components [7, 46—48]. It is highly
probable that these receptors play a role not only in normal renal
development, but also in glomerular injury.
DR. JOHN T. HARRINOTON (Dean ad Interim, Tufts University
School of Medicine, Boston, Massachusetts): Could you review for
us what happens to a standard experimental model of diabetic
nephropathy if the animals are treated with aminoguanidine? Are
there changes in renal function, specifically, in the GFR? Are
there significant changes in proteinuria?
DR. VLASSARA: Over the past several years since the original
observations were made, practically every experimental diabetic
model has been studied. The majority of these studies, with the
exception of a few, agree on the beneficial effects of aminoguani-
dine on various aspects of either morphologic or functional
damage that occurs with diabetes. Although inhibition of protein-
uria has been well documented, I have not seen any reports
referring specifically to studies of creatinine clearance or GFR in
rats.
DR. HARRINOTON: I have a followup question. What is the status
of clinical trials of aminoguanidine in humans?
DR. VLASSARA: Clinical trials (phase II and III) are currently in
progress in many centers in the United States and Europe. I think
Dr. Williams is one of the participants in this study; perhaps he
can provide his own insight. The United States trial has been
going on for approximately a year and a half, and more than 200
patients with diabetic nephropathy are involved so far. The central
aim is to determine whether the rate of progression of diabetic
nephropathy, in terms of serum creatinine and proteinuria, can be
slowed.
In terms of adverse effects that have been noted, a temporary
elevation of liver function tests in these patients, occurring
infrequently in the first two months, is apparently transient and
mild. The patients are maintained on the medication. The second
side effect has been a transient reduction in hematocrit in certain
cases. There has not been any major concern about these findings
up to now. Dr. Williams, would you like to add anything to this?
DR. MARK E. WILLIAMS (Director of Dialysis, Joslin Diabetes
Center and Deaconess Hospital, Boston, Massachusetts): Because of
early concerns about gastritis in humans, upper endoscopy was
performed in enrollees at study initiation and six weeks later. This
initial cohort of patients has been evaluated by the U.S. Food and
Drug Administration, and endoscopy is no longer a requirement
of patients enrolled in the trial.
Your presentation emphasized the importance of renal dys-
function in the rise of small AGE compounds in the circulation.
Would you elaborate further on where toxicity might arise from
these smaller-molecular-weight AGEs, which would be cleared
normally by the kidneys? Why should they be toxic in comparison
to the more complex AGEs that you mentioned? What is the fate
of the low-molecular-weight AGEs with regard to receptor up-
take? How would you predict they might affect tissue function and
cause tissue damage?
DR. VLASSARA: The chemistry of AGEs is indeed complex, and
relatively few compounds are known as biologically important.
Notoriously difficult to isolate and purify, AGEs remain vastly
heterogeneous as a class. Many AGEs at their final stages reflect
irreversible cross-links, or permanent "locks" between a reactive
glycation intermediate attached on one peptide and an amino
group that belongs to another protein or peptide. Once the
cross-link is formed, the AGE produced can be referred to as a
no-longer-reactive glycation product, usually linking up two or
more peptides of various sizes. Small AGE peptides are thought
to represent cleavage products generated as a result of normal
proteolysis of tissue proteins, which can contain reactive or
non-reactive AGEs. Normal tissue turnover and repair systems
degrade glycated proteins, partially hydrolyzing the modified
proteins and releasing low-molecular-weight peptides, bearing a
plethora of "reactive" intermediates in addition to the nonreac-
tive AGEs. This class of still chemically active intermediates will
cross-link to tissue and plasma proteins, if they are not excreted
efficiently in the urine, to form "second-" and "third-generation"
AGEs. Thus, in the presence of progressive renal impairment,
uncleared AGEs reach high levels. Such high concentrations of
AGEs in tissues and in the circulation can be considered "toxic"
in view of the multiple adverse cellular and tissue responses
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elicited via the AGE-receptor system or via direct chemical
impact.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): I'm interested in factors that determine the
variability of tissue and serum levels of AGEs in diabetic subjects
and the relationship among these factors and susceptibility to
vascular complications. Particularly, I'm interested in the ne-
phropathy. As you know, only 30% to 40% of type-I diabetics
develop nephropathy, and glucose levels appear to be only part of
the explanation. In particular, have there been analyses of stored
blood samples to determine the relationship between serum AGE
levels and diabetic complications?
DR. VLASSARA: Several recent studies have determined a close
relationship between tissue AGEs, especially in skin, and stage of
development of a number of complications [11, 17]. We have
recently obtained preliminary evidence pointing to a similar
correlation between plasma proteins, for example, ApoB-LDL
and severity of macrovascular disease in diabetic and non-diabetic
individuals with or without nephropathy [121. There is no doubt
that glycemic control is a major, but not the sole, key factor in
diabetic nephropathy. Epidemiologic data clearly suggest that
genetically determined susceptibilities exist, the expression of
which may depend on abnormal biochemical events, namely,
excessive AGE formation.
DR. LEVEY: What are some of the factors that determine the
variability in tissue and AGE levels within diabetics?
DR. VLASSARA: Of course, poor glycemic control with long-term
sustained hyperglycemia accelerates the rate of AGE formation
and deposition within the tissues. Another determinant of tissue
burden of AGEs is now believed to be the abundance and level of
efficiency of the cellular AGE-receptor system. It is anticipated
that individual differences that are genetically determined exist
regarding this important mechanism for removal and degradation
of AGEs. A recently recognized, and perhaps the most critical,
factor determining total-body AGE burden is renal function, as
discussed today. The last two factors are subject to genetically
determined susceptibilities to dysfunction, thus far unidentified,
yet actively investigated.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): Which component of AGE does your assay
detect? I presume that assays are picking up a wide range of
AGEs, some linked to proteins, lipids, etc.
DR. VLASSARA: The assays that we have referred to so far
included first a radioreceptor assay, which was based on AGE
recognition by the AGE receptor of intact macrophages. We no
longer use that assay because it was quite cumbersome. The
currently used assay is based on an AGE-ELISA system that
utilizes well-characterized polyclonal antibodies, and more re-
cently monoclonal anti-AGE antibodies. Regarding the precise
structure of the AGEs that these assays recognize, it is extremely
difficult to tell. Neither antibody recognizes any of the known
AGEs, including FF1, pentosidine, pyrraline, AFGP, etc. We
suspect that although both these antibodies recognize AGE
structures that exist in vivo and that are biologically relevant,
there might not be such a thing as a single, biologically important
AGE structure.
DR. PEREIRA: The reason I ask is because of the studies that you
conducted on dialysis membranes. A synthetic membrane, F8, is
not really a conventional membrane, while the commonly used
AN69 happens to be a highly negatively charged membrane. I
believe that adsorption and filtration need to be evaluated sepa-
rately while studying clearance of AGEs by dialysis membranes.
DR. VLASSARA: You are correct. In in-vitro studies on AGE
mass balance performed on these two high-efficiency, biocompat-
ible dialysis membranes by Dr. Steven Fishbane (Winthrop-
University Hospital, New York), a greater degree of adsorption
(threefold) was exhibited by the high-flux AN69 filter, which was
independent of an equally greater filtration rate [68]. As far as we
know, this was the first true comparison between low-flux and
high-flux dialyzers, where the issue is focused on the clearance of
larger molecules, for example, AGE peptides.
DR. RICHARD LAFAYETITE (Division of Nephrology, New England
Medical Center): Have any studies been done using inhibitors of
the formation of AGEs in terms of non-diabetic models of
sclerosis, either immune or non-immune, such as remnant kid-
neys, or nephritis models of progressive renal disease?
DR. VLASSARA: I believe such studies are currently ongoing in
other laboratories.
DR. DEBBIE BEASLEY (Division of Nephrology, New England
Medical Center): In the studies in which you've given aminogua-
nidine in vivo, do those concentrations of aminoguanidine inhibit
inducible nitric oxide synthase and, if so, how do you distinguish
those effects from effects on AGE formation?
DR. VLASSARA: Although aminoguanidine is capable of inhib-
iting nitric oxide synthase very well, it would appear that it does so
at much higher concentrations than those used in in-vivo studies.
Thus this effect has not presented itself as a problem as yet.
However, as we gather more information and experience from
in-vivo studies, our conclusions might have to be adjusted accord-
ingly.
DR. MADIAS: Is sorbitol or fructose involved in glycation? If it is,
is it known whether aldose reductase inhibitors can influence the
level of glycation products?
DR. VLASSARA: It is certainly possible, given that both sorbitol
and fructose can easily contribute to the generation of intracellu-
lar AGEs [69]. However, further studies are required to confirm
the specific effect of aldose reductase inhibitors on AGEs and
their toxicity.
DR. MADIAS: Does glycation of low-density lipoprotein change
its susceptibility to oxidation?
DR. VLASSARA: Yes. During glycation of the apoprotein or the
lipid particle of LDL, oxidation-reduction rearrangements occur
that can generate free radicals sufficient to induce fatty acid
oxidation. Consistent with this, a close correlation was found
between AGE modification and oxidation of LDL in vitro, as well
as in vivo in patients with diabetes and/or renal failure. Accord-
ingly, aminoguanidine protects not only against AGE, but also
against oxidative modification of LDL, thus expanding its thera-
peutic spectrum against atherosclerosis.
Reprint requests to Dr. H. Viassara, Laboratoiy of Diabetes and Aging,
Picower Institute for Medical Research, Manhasset, New York 11030, USA.
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